[Prostate cancer: future strategies for chemotherapy management].
作者信息
Fizazi K
机构信息
Institut Gustave-Roussy, 14, avenue Paul-Vaillant-Couturier, 94800 Villejuif, France.
出版信息
Ann Urol (Paris). 2007 Oct;41 Suppl 3:S77-9. doi: 10.1016/s0003-4401(07)80514-6.
Abstract
Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009-2010.
摘要
相似文献
1
[Prostate cancer: future strategies for chemotherapy management].
Ann Urol (Paris). 2007 Oct;41 Suppl 3:S77-9. doi: 10.1016/s0003-4401(07)80514-6.
2
Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
Clin Prostate Cancer. 2003 Mar;1(4):212-4. doi: 10.1016/s1540-0352(11)70004-x.
3
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.
4
Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Cancer Chemother Pharmacol. 2013 Nov;72(5):1055-61. doi: 10.1007/s00280-013-2291-x. Epub 2013 Sep 17.
5
Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
Int J Urol. 2009 Aug;16(8):687-91. doi: 10.1111/j.1442-2042.2009.02341.x. Epub 2009 Jul 8.
6
Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Semin Oncol. 1999 Oct;26(5 Suppl 17):49-54.
7
Docetaxel in prostate cancer.
Anticancer Drugs. 2001 Feb;12 Suppl 1:S17-20.
8
[Docetaxel and prostate cancer].
Bull Cancer. 2004 Feb;91(2):172-7.
9
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Urology. 2003 Apr;61(4):774-80. doi: 10.1016/s0090-4295(02)02519-0.
10
Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
J Urol. 2003 May;169(5):1729-34. doi: 10.1097/01.ju.0000062500.75703.2c.
Zotero 插件